These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6984388)

  • 21. [Augmentation of the anti-tumor activity of regional lymph node lymphocytes and spleen cells of tumor-bearing mice by culture with T cell growth factor in vitro--a comparison of the intestinal cancer model and footpad cancer model].
    Hori T; Kan N; Inamoto T; Nio Y; Ohgaki K; Kodama H; Tobe T
    Nihon Geka Gakkai Zasshi; 1986 Mar; 87(3):287-96. PubMed ID: 3487027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer cell activity and autologous tumor killing activity in cancer patients: overlapping involvement of effector cells as determined in two-target conjugate cytotoxicity assay.
    Uchida A; Yanagawa E
    J Natl Cancer Inst; 1984 Nov; 73(5):1093-100. PubMed ID: 6593485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma.
    Grazioli L; Sensi M; Parmiani G
    Cancer Immunol Immunother; 1987; 24(3):237-43. PubMed ID: 2954636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes.
    Schirrmacher V; Bosslet K; Shantz G; Clauer K; Hübsch D
    Int J Cancer; 1979 Feb; 23(2):245-52. PubMed ID: 83969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells.
    Kedar E; Ikejiri BL; Sredni B; Bonavida B; Herberman RB
    Cell Immunol; 1982 May; 69(2):305-29. PubMed ID: 6980720
    [No Abstract]   [Full Text] [Related]  

  • 27. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A; Muul LM; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
    Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
    Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
    Spiess PJ; Yang JC; Rosenberg SA
    J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells.
    Itoh K; Platsoucas CD; Balch CM
    Cell Immunol; 1987 Sep; 108(2):495-500. PubMed ID: 3113744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of human cytotoxic T lymphocytes against fresh autologous and allogeneic solid tumors by mixed lymphocyte tumor cell culture with T cell growth factor.
    Ichino Y; Ishikawa T
    Gan; 1984 May; 75(5):436-41. PubMed ID: 6235143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities.
    Kurt RA; Park JA; Panelli MC; Schluter SF; Marchalonis JJ; Carolus B; Akporiaye ET
    J Immunol; 1995 Apr; 154(8):3969-74. PubMed ID: 7706735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation and reactivity of host effectors associated with the manifestation of concomitant tumor immunity.
    Akporiaye ET; Kudalore M; Stevenson AP; Kraemer PM; Stewart CC
    Cancer Res; 1988 Mar; 48(5):1153-8. PubMed ID: 3257713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes.
    Rabinowich H; Cohen R; Bruderman I; Steiner Z; Klajman A
    Cancer Res; 1987 Jan; 47(1):173-7. PubMed ID: 3491673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.
    Leshem B; Kedar E
    J Exp Med; 1990 Apr; 171(4):1057-71. PubMed ID: 2139097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cells mediating specific in vitro cytotoxicity. I. Detection of receptor-bearing lymphocytes.
    Golstein P; Erik MD; Svedmyr AJ; Wigzell H
    J Exp Med; 1971 Dec; 134(6):1385-402. PubMed ID: 5001703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disaggregation of human solid tumours by combined mechanical and enzymatic methods.
    Engelholm SA; Spang-Thomsen M; Brünner N; Nøhr I; Vindeløv LL
    Br J Cancer; 1985 Jan; 51(1):93-8. PubMed ID: 3966975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactivity of tumor-infiltrating, blood, spleen and lymph node lymphocytes against syngeneic glioma target cells.
    Stavrou D; Bilzer T; Anzil AP; Hultén M; Kaldrymidou E
    Anticancer Res; 1981; 1(3):125-34. PubMed ID: 7342850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro cytotoxicity and transplantation protection by autologous natural and activated killer cells against an in vitro transformed tumorigenic fibroblast line. A case study.
    Wilhelm SA; Mukherji B
    J Clin Invest; 1985 Apr; 75(4):1162-8. PubMed ID: 3988936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
    Rodolfo M; Salvi C; Parmiani G
    Cancer Immunol Immunother; 1989; 28(2):136-42. PubMed ID: 2783888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.